P
Paul Nathan
Researcher at Northwood University
Publications - 213
Citations - 17048
Paul Nathan is an academic researcher from Northwood University. The author has contributed to research in topics: Melanoma & Trametinib. The author has an hindex of 44, co-authored 181 publications receiving 13804 citations. Previous affiliations of Paul Nathan include John Radcliffe Hospital & Aix-Marseille University.
Papers
More filters
Journal ArticleDOI
First-line avelumab + axitinib therapy in patients (pts) with advanced renal cell carcinoma (aRCC): Results from a phase Ib trial.
Toni K. Choueiri,James Larkin,Mototsugu Oya,Fiona C Thistlethwaite,Marcella Martignoni,Paul Nathan,Thomas Powles,David F. McDermott,Paul B. Robbins,David D. Chism,Daniel C. Cho,Michael B. Atkins,Michael S. Gordon,Sumati Gupta,Hirotsugu Uemura,Yoshihiko Tomita,Anna Compagnoni,Alessandra di Pietro,Brian I. Rini +18 more
TL;DR: JAVELIN Renal 100 is a phase Ib study evaluating safety and clinical activity of avelumab + axitinib in treatment-naive pts with aRCC; updated results are reported here.
Journal ArticleDOI
Rationale for Immune Checkpoint Inhibitors Plus Targeted Therapy in Metastatic Melanoma: A Review
TL;DR: This review outlines the rationale and preclinical evidence that support immune checkpoint inhibitor plus targeted therapy combination and sequencing strategies in melanoma and highlights the results available to date from clinical trials exploring these approaches to treatment.
Journal ArticleDOI
Redirected T cell lysis in patients with metastatic uveal melanoma with gp100-directed TCR IMCgp100: Overall survival findings.
Takami Sato,Paul Nathan,Leonel Hernandez-Aya,Joseph J. Sacco,Marlana Orloff,Jennifer Visich,Nicola Little,Ann-Marie Hulstine,Christina M. Coughlin,Richard D. Carvajal +9 more
TL;DR: A bispecific biologic comprised of a soluble T cell receptor recognizing the gp100 antigen fused to a scFV anti-CD3 and redirects T cell lysis of melanoma cells expressi...
Journal ArticleDOI
BRAF mutation testing algorithm for vemurafenib treatment in melanoma: recommendations from an expert panel.
David Gonzalez,L. Fearfield,Paul Nathan,Philippe Taniere,Andrew J Wallace,E. Brown,Catherine A. Harwood,J. Marsden,Sean Whittaker +8 more
TL;DR: Vemurafenib is the first licensed inhibitor of mutated BRAF, and offers a new first‐line option for patients with unresectable or metastatic melanoma who harbour BRAF mutations, and was developed in conjunction with a companion diagnostic.
Journal ArticleDOI
Current role of sentinel lymph node biopsy in the management of cutaneous melanoma: A UK consensus statement.
Howard Peach,Ruth E Board,Martin G. Cook,Pippa Corrie,Sally Ellis,Jenny L. C. Geh,P King,G Laitung,J.M.G. Larkin,J Marsden,Mark R. Middleton,Marc Moncrieff,Paul Nathan,B Powell,R Pritchard-Jones,Simon Rodwell,Neil Steven,Paul Lorigan +17 more
TL;DR: A multi-disciplinary consensus meeting involving many melanoma experts from the UK was convened in May 2018 and the conclusions reached were agreed by the clinicians attending the meeting and then externally peer reviewed.